Sharekhan has given Buy recommendation for Sanofi India with a target price of Rs. 9250 in its research report issued on Mar 02, 2022

Sharekhan’s research report on Sanofi India

Sanofi India Limited (Sanofi) had hosted an investors’ call to discuss business updates and the commentary was positive, pointing towards a healthy growth outlook. Sanofi’s three focus areas – accelerating growth in diabetology, fortify its presence in established products & build brands in consumer products are the key growth drivers. Sanofi aims to outpace growth in the covered therapy areas, while overall the company expects to grow in line with the industry, which bodes well. Divestment of slow moving business, which were a drag on the growth and leveraging digital to expand reach would drive OPM expansion leading to a double digit earnings CAGR. Highe growth visibility from chronics, strong and debt-free balance sheet, sturdy dividends, are key positives.


We retain Buy with an unchanged PT of Rs. 9,250.

More Info

At 12:32 hrs Sanofi India was quoting at Rs 7,188.00, down Rs 61.20, or 0.84 percent.

It has touched an intraday high of Rs 7,240.00 and an intraday low of Rs 7,166.00.

It was trading with volumes of 1,046 shares, compared to its thirty day average of 997 shares, an increase of 4.93 percent.

In the previous trading session, the share closed up 0.11 percent or Rs 8.10 at Rs 7,249.20.

The share touched its 52-week high Rs 9,300.00 and 52-week low Rs 6,949.35 on 10 August, 2021 and 27 January, 2022, respectively.

Currently, it is trading 22.71 percent below its 52-week high and 3.43 percent above its 52-week low.

Market capitalisation stands at Rs 16,554.41 crore.

Leave a Reply

Your email address will not be published.